Provided by Tiger Trade Technology Pte. Ltd.

Celldex Therapeutics

31.65
-0.5300-1.65%
Post-market: 32.000.3500+1.11%19:38 EDT
Volume:2.41M
Turnover:76.17M
Market Cap:2.48B
PE:-7.29
High:32.54
Open:32.26
Low:30.98
Close:32.18
52wk High:45.14
52wk Low:22.10
Shares:78.49M
Float Shares:73.02M
Volume Ratio:1.22
T/O Rate:3.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3401
EPS(LYR):-3.9000
ROE:-43.88%
ROA:-27.62%
PB:3.48
PE(LYR):-8.12

Loading ...

Celldex Therapeutics Inc: Favorable Safety Profile Consistent with Prior Studies, Including with New 450mg Loading Dose and up to 300mgq4w Regimen

THOMSON REUTERS
·
Jul 22

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

THOMSON REUTERS
·
Jul 22

Celldex Therapeutics - Phase 3 Csu Topline Data Expected Sept/oct 2026; Phase 3 Sd and Coldu Enrollment on Track

THOMSON REUTERS
·
Jul 22

Celldex Therapeutics is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 20

Celldex price target raised to $100 from $90 at Guggenheim

TIPRANKS
·
Jul 20

Celldex Initiates Search for New CFO Ahead of Martin's Retirement

Dow Jones
·
Jul 16

Celldex CFO Sam Martin to Retire in 2027, Stays Through March 2027 Transition

Reuters
·
Jul 16

Celldex Announces Planned Transition of Chief Financial Officer

THOMSON REUTERS
·
Jul 16

Celldex Therapeutics - Celldx CFO SAM Martin Plans to Retire in 2027

THOMSON REUTERS
·
Jul 16

Celldex Therapeutics (CLDX) Is Up 8.8% After Broad Russell Growth Index Additions Has The Bull Case Changed?

Simply Wall St.
·
Jul 06

Celldex Therapeutics (CLDX) Enters Russell Growth Indexes As Barzolvolimab Data Puts Valuation In Focus

Simply Wall St.
·
Jul 02

Celldex Therapeutics Shareholders Approve 3,400,000-share Increase to 2021 Equity Plan at Annual Meeting

Reuters
·
Jun 26

Celldex Therapeutics (CLDX) Stock Could Be 61% Below Fair Value After New Trial Data

Simply Wall St.
·
Jun 20

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now

InvestorPlace
·
Jun 19

Why Celldex Therapeutics (CLDX) Is Up 12.2% After CSU Drug Data Suggest Disease Modification Potential

Simply Wall St.
·
Jun 18

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 15

Celldex Therapeutics Price Target Maintained With a $42.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 15

Celldex presents long-term results from Phase 2 study of barzolvolimab

TIPRANKS
·
Jun 15

Celldex presents first-in-human results for CDX-622

TIPRANKS
·
Jun 15

Celldex Therapeutics Says Barzolvolimab Meets Primary Efficacy Endpoint In Phase 2 CSU Study

Reuters
·
Jun 14